Editas Medicine (EDIT) Capital Expenditures (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Capital Expenditures of -$1000.0 for Q3 2025, down 100.03% year-over-year from $2.9 million in Q3 2024, and up 99.9% quarter-over-quarter from -$1.0 million in Q1 2025.
Editas Medicine (EDIT) Capital Expenditures (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Capital Expenditures for 11 consecutive years, with -$1000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Capital Expenditures fell 100.03% year-over-year to -$1000.0; the TTM figure through Sep 2025 stood at -$486000.0 (down 105.07% YoY), while the FY2024 annual figure was $8.8 million, up 87.03% from the prior year.
- Capital Expenditures rose to -$1000.0 in Q3 2025 per EDIT's latest filing, from -$1.0 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $3.5 million in Q2 2024 and bottomed at -$1.0 million in Q1 2025.
- Historically, Capital Expenditures has averaged $1.4 million across 5 years, with a median of $1.3 million in 2023.
- Annual changes were most pronounced in 2024 — Capital Expenditures surged 1122.18% — and 2025, when it slumped 154.78%.
- Editas Medicine's Capital Expenditures stood at $2.8 million in 2021, then slumped by 78.07% to $624000.0 in 2022, then soared by 109.46% to $1.3 million in 2023, then tumbled by 58.68% to $540000.0 in 2024, then slumped by 100.19% to -$1000.0 in 2025.
- Business Quant data shows EDIT's Capital Expenditures at -$1000.0 in Q3 2025, -$1.0 million in Q1 2025, and $540000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Mar 31, 2025 | -1.03 Mn |
| Mar 31, 2025 | -1.03 Mn |
| Dec 31, 2024 | 540,000.00 |
| Dec 31, 2024 | 540,000.00 |
| Sep 30, 2024 | 2.92 Mn |
| Sep 30, 2024 | 2.92 Mn |
| Jun 30, 2024 | 3.49 Mn |
| Jun 30, 2024 | 3.49 Mn |
| Mar 31, 2024 | 1.87 Mn |
| Mar 31, 2024 | 1.87 Mn |
| Dec 31, 2023 | 1.31 Mn |
| Dec 31, 2023 | 1.31 Mn |
| Sep 30, 2023 | 239,000.00 |
| Sep 30, 2023 | 239,000.00 |
| Jun 30, 2023 | 1.33 Mn |
| Jun 30, 2023 | 1.33 Mn |
| Mar 31, 2023 | 1.84 Mn |
| Mar 31, 2023 | 1.84 Mn |